Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 304 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HPV Infections Clear all

Conditions: Papillomavirus Infections
Interventions: 851B; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 88
States / cities: Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more

Conditions: HIV Infection
Interventions: HPV vaccine for strains -6, -11, -16, and -18; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 23 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: Oropharyngeal Cancer, Human Papilloma Virus
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions: Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery; Biological · Other · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Human Papilloma Virus, Human Papilloma Virus Vaccine
Interventions: CDC 4 Pillars Program; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Albany, Georgia • Atlanta, Georgia • Lithonia, Georgia

Conditions: Human Papillomavirus
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 9 Years to 26 Years · Female only
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Infections, Papillomavirus
Interventions: Cervarix™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 25 Years · Female only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: San Francisco, California • Augusta, Georgia • Bardstown, Kentucky + 10 more

Conditions: Warts
Interventions: Microwave Treatment (Swift System), Cryotherapy; Device
Lead sponsor: Blackwell Device Consulting; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Miami, Florida • Palm Harbor, Florida • Tampa, Florida + 3 more

Conditions: Human Papilloma Virus, Dysplasia, CIN1, CIN2
Interventions: AHCC 3 grams once a day, Placebo; Dietary Supplement · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
Interventions: imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis; Drug · Device · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 35 Years and older
Enrollment: 4,446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 24
States / cities: Los Angeles, California • Palm Springs, California • San Francisco, California + 13 more

Conditions: STD
Interventions: Not listed
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years to 26 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Papillomavirus Infections
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions: Gardasil, Survey; Biological · Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 26 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasm Cervix
Interventions: Curcumin C3 Complex, Placebo; Drug
Lead sponsor: Lisa Flowers; Other
Eligibility: 21 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus Infection
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions: VP-102, Vehicle; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Miami, Florida • Saint Augustine, Florida • Meridian, Idaho + 13 more

Conditions: Cervical Intraepithelial Neoplasia
Interventions: Placebo, RO5217790; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Common Wart
Interventions: A-101, vehicle; Drug · Other
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 24
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 21 more

Conditions: Uterine Cervical Neoplasm, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Uterine Cervical Diseases, Uterine Diseases, Cervical Cancer, Cervical Dysplasia, Human Papilloma Virus, HPV-Related Cervical Carcinoma, HPV Infection, HPV-Related Malignancy
Interventions: Usual Care, Education, Direct Mail, Opt-in; Other · Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 30 Years to 64 Years · Female only
Enrollment: 32,771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Papillomatosis, HIV Infections
Interventions: Interferon-alpha, placebo; Drug · Other
Lead sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more

Conditions: HIV/AIDS, HPV Infection
Interventions: ORCHID; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Head and Neck Cancer, HPV (Human Papillomavirus)-Associated Carcinoma, Oropharyngeal
Interventions: research blood draw and tissue biopsy; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Papillomavirus
Interventions: Cohort: 3000 men examined every 6 months for 4 years., Pilot study: 150 men examined every 6 months for 4 years.; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 1,431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: High-risk HPV Infection and Biopsy-proven CIN1
Interventions: R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7; Biological
Lead sponsor: PDS Biotechnology Corp.; Industry
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Port Jefferson, New York • The Bronx, New York

Search by objective public record fields.

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

Men and Women Offering Understanding of Throat HPV

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study

Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer

Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America

Microwave Treatment of Common and Plantar Warts

Phase II Evaluation of AHCC for the Eradication of HPV Infections

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Study of Oral Papillomavirus In Teens and Twenties

High-Risk HPV Infections in Women Aged 25 to 65

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Topical Curcumin for HPV Related Cervical Disease

Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection

Study of A-101 Topical Solution for the Treatment of Common Warts

Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial

Treatment of Oral Warts in HIV+ Patients

ORCHID: An Online Intervention for Persons With HIV (Miami)

Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation

Natural History of HPV Infection in Men: The HIM Study

An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101